Literature DB >> 19353579

Analysis of full and partial agonists binding to beta2-adrenergic receptor suggests a role of transmembrane helix V in agonist-specific conformational changes.

Vsevolod Katritch1, Kimberly A Reynolds, Vadim Cherezov, Michael A Hanson, Christopher B Roth, Mark Yeager, Ruben Abagyan.   

Abstract

The 2.4 A crystal structure of the beta(2)-adrenergic receptor (beta(2)AR) in complex with the high-affinity inverse agonist (-)-carazolol provides a detailed structural framework for the analysis of ligand recognition by adrenergic receptors. Insights into agonist binding and the corresponding conformational changes triggering G-protein coupled receptor (GPCR) activation mechanism are of special interest. Here we show that while the carazolol pocket captured in the beta(2)AR crystal structure accommodates (-)-isoproterenol and other agonists without steric clashes, a finite movement of the flexible extracellular part of TM-V helix (TM-Ve) obtained by receptor optimization in the presence of docked ligand can further improve the calculated binding affinities for agonist compounds. Tilting of TM-Ve towards the receptor axis provides a more complete description of polar receptor-ligand interactions for full and partial agonists, by enabling optimal engagement of agonists with two experimentally identified anchor sites, formed by Asp113/Asn312 and Ser203/Ser204/Ser207 side chains. Further, receptor models incorporating a flexible TM-V backbone allow reliable prediction of binding affinities for a set of diverse ligands, suggesting potential utility of this approach to design of effective and subtype-specific agonists for adrenergic receptors. Systematic differences in capacity of partial, full and inverse agonists to induce TM-V helix tilt in the beta(2)AR model suggest potential role of TM-V as a conformational "rheostat" involved in the whole spectrum of beta(2)AR responses to small molecule signals. (c) 2009 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19353579      PMCID: PMC2693451          DOI: 10.1002/jmr.949

Source DB:  PubMed          Journal:  J Mol Recognit        ISSN: 0952-3499            Impact factor:   2.137


  45 in total

1.  Use of the substituted cysteine accessibility method to study the structure and function of G protein-coupled receptors.

Authors:  Jonathan A Javitch; Lei Shi; George Liapakis
Journal:  Methods Enzymol       Date:  2002       Impact factor: 1.600

2.  Functional differences between full and partial agonists: evidence for ligand-specific receptor conformations.

Authors:  R Seifert; K Wenzel-Seifert; U Gether; B K Kobilka
Journal:  J Pharmacol Exp Ther       Date:  2001-06       Impact factor: 4.030

3.  Catechol-binding serines of beta(2)-adrenergic receptors control the equilibrium between active and inactive receptor states.

Authors:  C Ambrosio; P Molinari; S Cotecchia; T Costa
Journal:  Mol Pharmacol       Date:  2000-01       Impact factor: 4.436

4.  Serine and threonine residues bend alpha-helices in the chi(1) = g(-) conformation.

Authors:  J A Ballesteros; X Deupi; M Olivella; E E Haaksma; L Pardo
Journal:  Biophys J       Date:  2000-11       Impact factor: 4.033

5.  Mutation of Asn293 to Asp in transmembrane helix VI abolishes agonist-induced but not constitutive activity of the beta(2)-adrenergic receptor.

Authors:  Annette Hannawacker; Cornelius Krasel; Martin J Lohse
Journal:  Mol Pharmacol       Date:  2002-12       Impact factor: 4.436

6.  Deterministic features of side-chain main-chain hydrogen bonds in globular protein structures.

Authors:  N Eswar; C Ramakrishnan
Journal:  Protein Eng       Date:  2000-04

7.  The forgotten serine. A critical role for Ser-2035.42 in ligand binding to and activation of the beta 2-adrenergic receptor.

Authors:  G Liapakis; J A Ballesteros; S Papachristou; W C Chan; X Chen; J A Javitch
Journal:  J Biol Chem       Date:  2000-12-01       Impact factor: 5.157

8.  Mutations inducing divergent shifts of constitutive activity reveal different modes of binding among catecholamine analogues to the beta(2)-adrenergic receptor.

Authors:  Renata Del Carmine; Caterina Ambrosio; Maria Sbraccia; Susanna Cotecchia; Adriaan P Ijzerman; Tommaso Costa
Journal:  Br J Pharmacol       Date:  2002-04       Impact factor: 8.739

9.  Beta2 adrenergic receptor activation. Modulation of the proline kink in transmembrane 6 by a rotamer toggle switch.

Authors:  Lei Shi; George Liapakis; Rui Xu; Frank Guarnieri; Juan A Ballesteros; Jonathan A Javitch
Journal:  J Biol Chem       Date:  2002-08-06       Impact factor: 5.157

10.  Sequential binding of agonists to the beta2 adrenoceptor. Kinetic evidence for intermediate conformational states.

Authors:  Gayathri Swaminath; Yang Xiang; Tae Weon Lee; Jacqueline Steenhuis; Charles Parnot; Brian K Kobilka
Journal:  J Biol Chem       Date:  2003-10-14       Impact factor: 5.157

View more
  55 in total

1.  Molecular mechanism of serotonin transporter inhibition elucidated by a new flexible docking protocol.

Authors:  Mari Gabrielsen; Rafał Kurczab; Aina W Ravna; Irina Kufareva; Ruben Abagyan; Zdzisław Chilmonczyk; Andrzej J Bojarski; Ingebrigt Sylte
Journal:  Eur J Med Chem       Date:  2011-10-20       Impact factor: 6.514

Review 2.  Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery.

Authors:  Terry Kenakin; Laurence J Miller
Journal:  Pharmacol Rev       Date:  2010-04-14       Impact factor: 25.468

Review 3.  Optical probes based on G protein-coupled receptors - added work or added value?

Authors:  A D Stumpf; C Hoffmann
Journal:  Br J Pharmacol       Date:  2015-12-19       Impact factor: 8.739

4.  Do crystal structures obviate the need for theoretical models of GPCRs for structure-based virtual screening?

Authors:  Hao Tang; Xiang Simon Wang; Jui-Hua Hsieh; Alexander Tropsha
Journal:  Proteins       Date:  2012-03-13

5.  A structural chemogenomics analysis of aminergic GPCRs: lessons for histamine receptor ligand design.

Authors:  A J Kooistra; S Kuhne; I J P de Esch; R Leurs; C de Graaf
Journal:  Br J Pharmacol       Date:  2013-09       Impact factor: 8.739

6.  Structure-based ligand discovery targeting orthosteric and allosteric pockets of dopamine receptors.

Authors:  J Robert Lane; Pavel Chubukov; Wei Liu; Meritxell Canals; Vadim Cherezov; Ruben Abagyan; Raymond C Stevens; Vsevolod Katritch
Journal:  Mol Pharmacol       Date:  2013-09-10       Impact factor: 4.436

Review 7.  Rastering strategy for screening and centring of microcrystal samples of human membrane proteins with a sub-10 microm size X-ray synchrotron beam.

Authors:  Vadim Cherezov; Michael A Hanson; Mark T Griffith; Mark C Hilgart; Ruslan Sanishvili; Venugopalan Nagarajan; Sergey Stepanov; Robert F Fischetti; Peter Kuhn; Raymond C Stevens
Journal:  J R Soc Interface       Date:  2009-06-17       Impact factor: 4.118

8.  The importance of valine 114 in ligand binding in beta(2)-adrenergic receptor.

Authors:  Makoto Arakawa; Naveena Yanamala; Jasbir Upadhyaya; Andrew Halayko; Judith Klein-Seetharaman; Prashen Chelikani
Journal:  Protein Sci       Date:  2010-01       Impact factor: 6.725

9.  Ligand-dependent perturbation of the conformational ensemble for the GPCR β2 adrenergic receptor revealed by HDX.

Authors:  Graham M West; Ellen Y T Chien; Vsevolod Katritch; Jovylyn Gatchalian; Michael J Chalmers; Raymond C Stevens; Patrick R Griffin
Journal:  Structure       Date:  2011-09-01       Impact factor: 5.006

Review 10.  The dopamine transporter: An unrecognized nexus for dysfunctional peripheral immunity and signaling in Parkinson's Disease.

Authors:  Phillip Mackie; Joe Lebowitz; Leila Saadatpour; Emily Nickoloff; Peter Gaskill; Habibeh Khoshbouei
Journal:  Brain Behav Immun       Date:  2018-03-15       Impact factor: 7.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.